Rapamycin
rapamycin · sirolimus
mTOR inhibitor with the strongest evidence of lifespan extension in animal models.
Grade
A
Strong
- Class
- mTOR / Autophagy
- Primary use
- mTOR inhibition
- Evidence strength
- high
- Last reviewed
- 2025-09-01
The claim
mTOR inhibitor with the strongest evidence of lifespan extension in animal models.
What the evidence says
Robust, consistent preclinical evidence across species. In humans: a drug with defined clinical indications; off-label 'longevity' use is experimental and must be managed only with a physician.
Key studies
- [1]
Rapamycin and lifespan extension (PubMed) · review
Robust lifespan extension in animal models.
PubMed ↗
Mechanism
Inhibition of the mTORC1 complex, with effects on autophagy, proteostasis and senescence.
Safety
Prescription drug with known adverse effects (immunosuppression, metabolic effects). It is not a supplement.
Dosage context
Intermittent regimens are studied in research; no approved longevity protocol.
From the field
Grade A for the strength of preclinical evidence — not an invitation to use: it's a drug, not a supplement.